Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

NCT06788912 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Neoplasm Malignant

Interventions

BIOLOGICAL: Pembrolizumab (neoadjuvant)
DRUG: Cisplatin
DRUG: Gemcitabine
DRUG: Pemetrexed
DRUG: Sacituzumab tirumotecan
DRUG: H1 receptor antagonist
DRUG: H2 receptor antagonist
DRUG: Acetaminophen (or equivalent)
DRUG: Dexamethasone (or equivalent)
DRUG: Carboplatin
BIOLOGICAL: Pembrolizumab (adjuvant)
DRUG: Paclitaxel
DRUG: Steroid mouthwash (dexamethasone or equivalent)

Sponsor

Merck Sharp & Dohme LLC